Carbaprostacyclin is a stable analog of prostacyclin (prostaglandin I
2) which can activate the prostacyclin receptor or PPARδ.
1,2,3 Carbaprostacyclin methyl ester is a more lipid soluble form of carbaprostacyclin. As a result, it may more readily enter cells to activate PPARδ. The biological activities of carbaprostacyclin methyl ester have not been studied.
1. Aubert, J., Ailhaud, G., and Negrel, R. Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells FEBS Lett. 397(1),117-121(1996).
2. Armstrong, R.A., Lawrence, R.A., Jones, R.L., et al. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors Br. J. Pharmacol. 97,657-668(1989).
3. Kurtz, M., Capobianco, E., Martínez, N., et al. Carbaprostacyclin, a PPARδ agonist, ameliorates excess lipid accumulation in diabetic rat placentas Life Sci. 86,781-790(2010).
